Pharmachemie tamoxifen
Executive Summary
Teva subsidiary receives full approval for generic tamoxifen 10 mg tablet May 31. AstraZeneca still has patent protection on the compound (Nolvadex) until Aug. 20, 2002, and litigation is pending. The approval reflects an April Washington, D.C. federal court decision vacating FDA's award of 180 days of generic exclusivity to Barr, which has marketed tamoxifen under a patent settlement with AstraZeneca since 1992 (1"The Pink Sheet" April 10, p. 3)
You may also be interested in...
AstraZeneca Nolvadex Patent Valid Until 2002, Firm Says After Court Ruling
AstraZeneca expects that generic competition to Nolvadex will be limited to Barr's "authorized" tamoxifen until Aug. 20, 2002, following a Boston federal court ruling against Teva/Pharmachemie.
AstraZeneca Nolvadex Patent Valid Until 2002, Firm Says After Court Ruling
AstraZeneca expects that generic competition to Nolvadex will be limited to Barr's "authorized" tamoxifen until Aug. 20, 2002, following a Boston federal court ruling against Teva/Pharmachemie.
Sen. Gorton Sets April Deadline For Alternatives To International Pricing Bill
Sen. Gorton (R-Wash.) is asking the pharmaceutical industry to come up with a proposal before the April 17 Easter recess to address the international disparity in pharmaceutical prices.